<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the incidence of <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> in an animal model of embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> to determine the safety of aspirin, <z:chebi fb="5" ids="28304">heparin</z:chebi>, and tissue plasminogen activator therapies </plain></SENT>
<SENT sid="1" pm="."><plain>We occluded the middle cerebral arteries of rabbits with labeled blood clots and administered either tissue plasminogen activator, <z:chebi fb="5" ids="28304">heparin</z:chebi>, aspirin, tissue plasminogen activator plus aspirin, tissue plasminogen activator plus <z:chebi fb="5" ids="28304">heparin</z:chebi>, or saline at various times after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Compared to saline controls, both the aspirin-only and the tissue plasminogen activator-plus-aspirin groups had a significantly higher incidence of <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo>, whereas the <z:chebi fb="5" ids="28304">heparin</z:chebi> and tissue plasminogen activator combination groups did not </plain></SENT>
<SENT sid="3" pm="."><plain>We conclude that aspirin antiplatelet therapy alone may increase the risk of hemorrhagic infarction, whereas <z:chebi fb="5" ids="28304">heparin</z:chebi> or tissue plasminogen activator therapy appears to be relatively safe </plain></SENT>
</text></document>